Jiatong Li

Dr. Jiatong Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in Cancer Letters
Verified
Journal Article
Closed access
SLShizhe Li
Shizhe Li
TCTing Chen
Ting Chen
JLJinxin Liu
Jinxin Liu
HZHe Zhang
He Zhang
JLJiatong Li
Jiatong Li
GSGuanning Shang
Guanning Shang

12 August 2020 in Research Square
Verified
Preprint
Open access
PDF file
BZBaohui Zhang
Baohui Zhang
TBTang Bufu
Tang Bufu
JGJianyao Gao
Jianyao Gao
JLJiatong Li
Jiatong Li
LKlingming kong
lingming kong
LQLing Qin
Ling Qin
BackgroundHypoxia plays an indispensable role in the development of hepatocellular carcinoma (HCC). However, there are few studies on the application of hypoxia molecules in the prognosis predicting of HCC. We aim to identify the hypoxia-related genes in HCC and construct reliable models for diagnosis, prognosis and recurrence of HCC patients as well as exploring the potential mechanism.MethodsDifferentially expressed genes (DEGs) analysis was performed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database and four clusters were determined by a consistent clustering analysis. Three DEGs closely related to overall survival(OS)were identified using Cox regression and LASSO analysis. Then the hypoxia-related signature was developed and validated in TCGA and International Cancer Genome Consortium (ICGC) database. The Gene Set Enrichment Analysis (GSEA) was performed to explore signaling pathways regulated by the signature. CIBERSORT was used for estimating the fractions of immune cell types.ResultsA total of 397 hypoxia-related DEGs in HCC were detected and three genes (PDSS1, CDCA8 and SLC7A11) among them were selected to construct a prognosis, recurrence and diagnosis model. Then patients were divided into high- and low-risk groups. Our hypoxia-related signature was significantly associated with worse prognosis and higher recurrence rate. The diagnostic model also accurately distinguished HCC from normal samples and nodules. Furthermore, the hypoxia-related signature could positively regulate immune response. Meanwhile, the high-risk group had higher fractions of macrophages, B memory cells and follicle-helper T cells, and exhibited higher expression of immunocheckpoints such as PD1and PDL1.ConclusionsAltogether, our study showed that hypoxia-related signature is a potential biomarker for diagnosis, prognosis and recurrence of HCC, and it provided an immunological perspective for developing personalized therapies.

8 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GZGuangqiang Zhang
Guangqiang Zhang
JLJuntan Li
Juntan Li
TCTing Chen
Ting Chen
JLJiatong Li
Jiatong Li
KSKai Sun
Kai Sun
GSGuanning Shang
Guanning Shang
Background: Despite advances in treatment strategies, osteosarcoma patients undergoing limb-salvage surgery (LSS) still face a considerable risk of recurrence and unsatisfactory long-term survival. Therefore, reliable pretreatment baseline prognostic assessment tools are needed to improve postoperative risk stratification and guide individualized treatment. Methods: This single-center retrospective prediction model development study analyzed 118 patients with pathologically confirmed osteosarcoma treated at Shengjing Hospital, China Medical University, between January 2019 and January 2025. After applying predefined inclusion and exclusion criteria, 81 patients were included in the final analysis. All predictors were defined as before-treatment baseline measurements at the diagnosis stage: alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) were serum biochemical markers, whereas fibrinogen (FIB) and D-dimer were plasma coagulation-related markers. Ki-67 index, age, sex, tumor size, and lung metastasis status were also assessed at this before-treatment baseline. A diagnosis-stage baseline prognostic model for overall survival (OS) among patients undergoing LSS was subsequently constructed. Internal validation of model performance was performed using bootstrap resampling only, with no external validation performed. Results: Kaplan–Meier analysis demonstrated 1-, 3-, and 5-year survival rates of 87.3%, 74.3%, and 64.1%, respectively. Survival curve analysis revealed that patients with elevated levels of all four laboratory biomarkers were associated with shorter OS. Multivariate Cox regression analysis revealed that baseline ALP remained independently associated with OS, while FIB showed borderline significance (p = 0.050). The final OS prognostic model incorporated ALP, LDH, FIB, and D-dimer. The apparent Harrell’s concordance index (C-index) of the model was 0.838 for the full dataset, with an optimism-corrected C-index of 0.780 after Bootstrap internal validation. The area under the receiver operating characteristic curve (AUC) of the model for predicting 1-, 3-, and 5-year OS in the full dataset was 0.831, 0.864, and 0.871, respectively; the optimism-corrected AUC values after Bootstrap validation were 0.771, 0.810, and 0.814. Conclusions: In this single-center retrospective cohort, higher baseline levels of ALP, LDH, FIB, and D-dimer were associated with adverse clinicopathological characteristics and poorer survival outcomes in patients with osteosarcoma. The LASSO-Cox-based prognostic model showed promising discrimination and calibration after internal Bootstrap validation. However, given the limited sample size and absence of external validation, these findings should be considered preliminary, and prospective multicenter external validation is required before the model can be considered for routine clinical implementation.